Key facts
- Revolution Medicines' new pancreatic cancer drug, Rasonque, has received US approval.
- The drug targets the RAS protein, a significant advance in treating pancreatic cancer.
- Rasonque is priced at over $475,000 annually, positioning it among the most expensive cancer treatments.
- Clinical trials showed Rasonque nearly doubled survival time for patients with an aggressive form of the disease.
- The drug is indicated for patients with metastatic disease who have undergone prior chemotherapy or are unsuitable for such regimens.
Revolution Medicines has secured US approval for Rasonque, a novel once-daily pill designed to treat advanced pancreatic cancer by targeting the RAS protein, a significant development in a field where such targets were long considered undruggable. The drug's list price is set at over $475,000 annually, placing it among the most expensive cancer treatments historically and highlighting a trend of escalating drug costs.
Rasonque represents a scientific breakthrough as one of the first medicines to broadly target the RAS protein, which is mutated in most pancreatic cancers and plays a crucial role in tumor growth. This approach marks a departure from previous efforts that focused on downstream targets. The drug's oral administration is also a key advantage, offering a more convenient option for patients, particularly those frail from advanced disease, compared to traditional infusions.
Clinical trials demonstrated Rasonque's efficacy, nearly doubling the survival time for patients with an aggressive form of the disease. In a late-stage study, patients treated with Rasonque lived for over 13 months, compared to 6.7 months for those receiving standard chemotherapy. The drug is approved for patients with metastatic disease who have already undergone chemotherapy or are not candidates for such regimens. Common side effects include rash and mouth sores.
The high price point is expected to face scrutiny from payers, insurers, and employers, despite potential rebates and discounts. Analysts, however, are optimistic about the drug's commercial prospects, with projections of over $9 billion in sales by 2032. The company's stock saw a positive reaction to the news, reflecting investor confidence in the drug's potential. The approval was expedited by the US Food and Drug Administration.